Brief: Expres2ion Announces Topline Results For Its Breast Cancer Vaccine

ExpreS2ion Biotech Holding AB

22/12/2021 07:33

Dec 22 (Reuters) - ExpreS2ion Biotech Holding AB
 EXPRS2.ST :
    * EXPRES2ION ANNOUNCES POSITIVE TOPLINE RESULTS FOR ITS
HER2-CVLP
BREAST CANCER VACCINE, DEMONSTRATING ANIMAL PROOF-OF-CONCEPT
    * ES2B-C001 DEMONSTRATED STRONG TUMOR-GROWTH INHIBITING
EFFECT IN
A MICE MODEL, REACHING MILESTONE AHEAD OF SCHEDULE
    * ANNOUNCES THAT ITS CAPSID VIRUS-LIKE PARTICLE (CVLP)
BREAST
CANCER VACCINE CANDIDATE ES2B-C001 DEMONSTRATED STRONG
TUMOR-GROWTH INHIBITING EFFECT IN A MICE MODEL, THUS REACHING AN
IMPORTANT PRE-CLINICAL MILESTONE AHEAD OF SCHEDULE
    * ANTI-HER2 ANTIBODIES FROM THESE STUDIES WERE FOUND TO
EFFECTIVELY INHIBIT TUMOR GROWTH IN HUMAN CANCER CELLS
    * ANTI-HER2 ANTIBODIES FROM THESE STUDIES WERE FOUND TO
EFFECTIVELY INHIBIT TUMOR GROWTH IN HUMAN CANCER CELLS.
THERAPEUTIC VACCINE IS BEING DEVELOPED TOWARDS FIRST IN HUMAN
CLINICAL TRIALS IN 2023
    * THERAPEUTIC VACCINE IS BEING DEVELOPED TOWARDS FIRST IN
HUMAN
CLINICAL TRIALS IN 2023.

Source text for Eikon:  ID:nWkr3xlDlK 
Further company coverage:  EXPRS2.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))